Pharmaceuticals - I V Fluids
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 613.03 | 565.83 | 608.49 | 567.75 | 344.64 |
Total Expenses | 568.39 | 527.90 | 572.08 | 542.64 | 343.87 |
Profit Before Tax | 44.64 | 37.93 | 36.41 | 48.55 | -8.04 |
Profit After Tax | 28.49 | 26.57 | 40.72 | 61.77 | -10 |
Operating Profit after Depreciation | 44.74 | 38.05 | 36.89 | 38.13 | 14.11 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 218.53 | 215.96 | 240.94 | 261.68 | 289.37 |
Total Non Current Assets | 267.30 | 278.25 | 301.78 | 321.82 | 349.77 |
Total Current Assets | 359.52 | 322.83 | 278.04 | 234.03 | 294 |
TOTAL ASSETS | 626.82 | 601.08 | 579.82 | 555.85 | 643.77 |
Total Shareholder's Fund | 487.55 | 460.34 | 440.45 | 400.28 | 323.37 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 37.29 | 36.63 | 41.10 | 131.84 | 77.60 |
Net Cash used in Investing Activities | -8.46 | -58.10 | -17.25 | 57.34 | -4.69 |
Net Cash used in Financing Activities | -1.08 | -0.57 | -9.48 | -162.24 | -73 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 586.53 | 547.84 | 585.14 | 532.39 | 323.81 |
Total Expenses | 539.88 | 507.51 | 540.47 | 514.77 | 321.26 |
Profit Before Tax | 46.65 | 40.33 | 44.67 | 41.06 | -6.26 |
Profit After Tax | 30.50 | 28.96 | 48.99 | 54.27 | -8.23 |
Operating Profit after Depreciation | 46.65 | 40.33 | 44.67 | 30.34 | 15.59 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 202.76 | 199.68 | 224.67 | 244.20 | 271.47 |
Total Non Current Assets | 280.26 | 290.70 | 314.25 | 333.08 | 360.33 |
Total Current Assets | 361 | 318.19 | 264.41 | 213.74 | 283.94 |
TOTAL ASSETS | 641.26 | 608.89 | 578.66 | 546.81 | 644.27 |
Total Shareholder's Fund | 508.59 | 478.05 | 449.41 | 400.18 | 332.25 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 35.38 | 28.05 | 41 | 132.34 | 77.75 |
Net Cash used in Investing Activities | -6.94 | -50.81 | -16.75 | 55.98 | -4.64 |
Net Cash used in Financing Activities | - | - | -9.13 | -161.88 | -72.35 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 167.45 | 108.61 | 195.16 | 143.42 | 167.72 |
Total Expenses | 162.53 | 97.35 | 175.69 | 131.43 | 149.93 |
Profit Before Tax | 9.07 | 6.85 | 17.46 | 7.78 | 14.34 |
Profit After Tax | 3.51 | 1.22 | 10.51 | 6.85 | 9.94 |
Operating Profit after Depreciation | 15.50 | 12.85 | 23.39 | 14.34 | 20.84 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 167.02 | 105.86 | 175.16 | 131.23 | 170.19 |
Total Expenses | 156.77 | 91.58 | 153.89 | 118.23 | 157.06 |
Profit Before Tax | 14.81 | 10.08 | 19.46 | 9.12 | 9.85 |
Profit After Tax | 9.26 | 4.45 | 12.51 | 8.19 | 5.45 |
Operating Profit after Depreciation | 20.96 | 15.84 | 25.18 | 15.42 | 16.06 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Venus Remedies Ltd | ₹295.05 | ₹394.39 |
Sun Pharmaceuticals Industries Ltd | ₹1,745.25 | ₹4,18,743.94 |
Divis Laboratories Ltd | ₹5,733.60 | ₹1,52,209.07 |
Cipla Ltd | ₹1,458.15 | ₹1,17,762.24 |
Torrent Pharmaceuticals Ltd | ₹3,357.15 | ₹1,13,616.11 |
Mankind Pharma Ltd | ₹2,488.40 | ₹1,02,663.15 |
25 Jan 2025, 09:23 am
21 Jan 2025, 11:48 am
31 Dec 2024, 01:43 pm
18 Oct 2024, 05:16 pm
24 Aug 2024, 10:36 am